Investigational Drug Information for Pyrotinib
✉ Email this page to a colleague
What is the development status for investigational drug Pyrotinib?
Pyrotinib is an investigational drug.
There have been 132 clinical trials for Pyrotinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2021.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Brain Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Shengjing Hospital.
There are six US patents protecting this investigational drug and ninety international patents.
Summary for Pyrotinib
US Patents | 6 |
International Patents | 90 |
US Patent Applications | 30 |
WIPO Patent Applications | 13 |
Japanese Patent Applications | 5 |
Clinical Trial Progress | Phase 1 (2021-07-01) |
Vendors | 30 |
Recent Clinical Trials for Pyrotinib
Title | Sponsor | Phase |
---|---|---|
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | Fudan University | Phase 2 |
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer | RenJi Hospital | Phase 3 |
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | Fudan University | Phase 3 |
Clinical Trial Summary for Pyrotinib
Top disease conditions for Pyrotinib
Top clinical trial sponsors for Pyrotinib
US Patents for Pyrotinib
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Pyrotinib | ⤷ Try a Trial | Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) | ⤷ Try a Trial |
Pyrotinib | ⤷ Try a Trial | Method for preparing tyrosine kinase inhibitor and derivative thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) | ⤷ Try a Trial |
Pyrotinib | ⤷ Try a Trial | Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor | JIANGSU HENGRUI MEDICINE CO., LTD. (Jiangsu, CN) SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (Shanghai, CN) | ⤷ Try a Trial |
Pyrotinib | ⤷ Try a Trial | 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (Shanghai, CN) | ⤷ Try a Trial |
Pyrotinib | ⤷ Try a Trial | Crystalline form I of tyrosine kinase inhibitor dimaleate and preparation methods thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) | ⤷ Try a Trial |
Pyrotinib | ⤷ Try a Trial | Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (Shanghai, CN) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Pyrotinib
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Pyrotinib | Australia | AU2017211737 | 2036-01-27 | ⤷ Try a Trial |
Pyrotinib | Brazil | BR112018014544 | 2036-01-27 | ⤷ Try a Trial |
Pyrotinib | Canada | CA3008701 | 2036-01-27 | ⤷ Try a Trial |
Pyrotinib | China | CN107405345 | 2036-01-27 | ⤷ Try a Trial |
Pyrotinib | China | CN108938586 | 2036-01-27 | ⤷ Try a Trial |
Pyrotinib | Denmark | DK3378479 | 2036-01-27 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |